Loading viewer...
investor_presentation
Format: PDF investor_presentation
Fiscal 2021 Fourth -Quarter & Full -Year Results July 26, 2021
Fiscal 2021 Fourth -Quarter & Full -Year Results
July 26, 20212*EBIT is defined as earnings (loss) before interest and taxes. Management uses EBIT, as defined, as a measure of operating
performance, since interest expense, net, essentially relates to corporate functions, as opposed to segment operations.($ in thousands, except per share and percent data)
2021 % 2020 % % Change
Net Sales 1,744,307 $ 1,458,962 $ 19.6
Cost of Sales 1,050,916 60.2 905,006 62.0
Gross Profit 693,391 39.8 553,956 38.0
SG&A 466,471 26.8 362,861 24.9
Restructuring Expense 5,826 0.3 14,344 1.0
Other Expense, Net 6,132 0.4 6,909 0.5
EBIT* (non-GAAP measure) 214,962 12.3 169,842 11.6 26.6
Interest Expense 21,425 1.2 22,372 1.5
Investment (Income) Expense, Net (10,716) (0.6) 615 0.0
Income Before Taxes 204,253 11.7 146,855 10.1
Provision for Income Taxes 47,889 2.7 37,680 2.6
Net Income 156,364 9.0 109,175 7.5 43.2
Less: Net Income (Loss) Attributable
to Noncontrolling Interests 217 0.0 (139) (0.0)
Net Income Attributable to RPM
Stockholders 156,147 $ 9.0 109,314 $ 7.5 42.8
Diluted EPS 1.20 $ 0.84 $ 42.9 Three Months Ended May 31,Consolidated Statements of Income
Fiscal 2021 Fourth -Quarter & Full -Year Results | July 26, 20213*EBIT is defined as earnings (loss) before interest and taxes. Management uses EBIT, as defined, as a measure of operating p erformance,
since interest expense, net, essentially relates to corporate functions, as opposed to segment operations.($ in thousands, except per share and percent data)
2021 % 2020 % % Change
Net Sales 6,106,288 $ 5,506,994 $ 10.9
Cost of Sales 3,701,129 60.6 3,414,139 62.0
Gross Profit 2,405,159 39.4 2,092,855 38.0
SG&A 1,664,026 27.3 1,548,653 28.1
Restructuring Expense 18,106 0.3 33,108 0.6
Other Expense, Net 13,639 0.2 12,066 0.2
Preview truncated — download the full document for the complete content.
investor_presentation
50 Pages
investor_presentation
Nova Eye Medical Limited
investor_presentation
UOB Group
Atomo Diagnostics 2020 Investor Update
investor_presentationinvestor_presentation
18 Pages
Atomo Diagnostics Limited